Characteristics of pretreatment drug resistance mutations in people living with human immunodeficiency virus type 1 in Henan Province,2023
Objective To monitor the subtype distributions and drug resistance mutations of human immunodeficiency virus(HIV)-l in people living with human immunodeficiency virus-1(PLWH)who had not experienced anti-retroviral therapy(ART)in Henan Province in 2023,so as to provide valuable data for understanding the transmission of HIV-1 resistant strains and selection of ART regimens in Henan Province.Methods The clinical data and drug resistance of PLWHs who had not experienced ART in the Sixth People's Hospital of Zhengzhou from January to December 2023 were collected.This study was a cross-sectional study.Plasma samples were collected from patients,and the partial HIV pol gene sequence and the full integrase gene sequence were amplified by reverse transcription-nested polymerase chain reaction.The subtypes of HIV-1 isolates were determined using the online REGA HIV-1 Subtyping Tool.Drug resistance mutations and antiviral drug susceptibility were analyzed by submitting the determined sequences to the Stanford HIV-1 drug resistance database.Results Among the 1 073 PLWHs who had not experienced ART,sequences in 1 042 were successfully amplified,giving a success rate of 97.11％.A total of 12 subtypes were detected,and the top five subtypes were circulating recombinant form(CRF)07_BC(43.76％,456/1 042),CRF01_AE(25.91％,270/1 042),B(20.92％,218/1 042),CRF55_01B(5.28％,55/1 042)and CRF08_BC(1.25％,13/1 042).The incidence of drug resistance mutation was 28.89％(301/1 042).Drug resistance mutation of non-nucleoside reverse transcriptase inhibitors(NNRTI),nucleotide reverse transcriptase inhibitors(NRTI),protease inhibitors(PI)and integrase inhibitors(INSTI)were 20.92％(218/1 042),4.03％(42/1 042),3.84％(40/1 042)and 2.98％(31/1 042),respectively.V179(12.96％,135/1 042),M184(2.40％,25/1 042),Q58(2.78％,29/1 042),and E157(1.44％,15/1 042)were the most common drug resistance mutation for NNRTIs,NRTIs,Pls and INSTls,respectively.Conclusions The distribution of HIV-1 subtypes is diverse,and the incidence of drug resistance mutation is moderate prevalent in PLWHs who have not experienced ART.Drug resistance testing in PLWHs before ART should be closely monitored.
HIVAntiretroviral therapyPretreatment drug resistance mutationSubtype
NETL
NSTL
万方数据
